Tumor Protein P53 (TP53) (full length) antibody
|Synonyms||p53, LFS1, TRP53, FLJ92943, P53, Trp53, MGC112612, brp53, drp53, fb40d06, wu:fb40d06, zgc:111919, TP53, bbl, bfy, bhy, p44, Tp53, tp53|
Alternatives Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunoprecipitation (IP)
|11 references available|
|Quantity||0.1 mg (0.5 mg/ml)|
|Price||Product not available in this region.|
|Immunogen||Recombinant full-length human p53|
|Cross-Reactivity||Mouse (Murine), Rat (Rattus)|
|Description||P53 is a 53 kD nuclear phosphoprotein that acts as a tumor suppressor protein, and is involved in inhibiting cell proliferation when DNA damage occurs. The gene for p53 is the most commonly mutated gene yet identified in human cancers. Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder and several other organs. The mutant p53 is overexpressed in a variety of transformed cells and the wildtype p53 forms specific complexes with several viral oncogenes including SV40 large T, E1B from adenovirus and E6 from human papilloma virus. Wildtype p53 plays a role as a checkpoint protein for DNA damage during the S-phase of the cell cycle. p53 migrates at a reduced molecular weight of 53 kDa. Clone G59-12 recognizes mutant and wild type human, rat and mouse p53 tumor suppressor protein. Recombinant full-length human p53 was used as immunogen.|
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
|Molecular Weight||53 kDa|
|Application Notes||Clone G59-12 conjugated to R-Phycoerythrin (PE) is suggested for flow cytometric analysis of p53. Positive control cell lines include SKBR-3 human breast carcinoma cells (ATCC HTB-30) and A431 human vulval carcinoma cells (ATCC CRL-1555). Jurkat T cells (ATCC TIB-152) or MCF-7 human breast carcinoma cells (ATCC HTB-22) are suggested as negative controls. Positive immunostaining is seen in a high proportion of breast and colon carcinomas. p53 staining is not typically detected in normal skin, brain, kidney, lung, stomach, or breast tissue.|
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at 4°C.|
|Research Area||Cancer, Cell Cycle, Transcription Factors, DNA/RNA, Apoptosis/Necrosis|
|Restrictions||For Research Use only|
Mørkve, Halvorsen, Stangeland et al.: "Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer." in: International journal of cancer. Journal international du cancer, Vol. 52, Issue 6, pp. 851-5, 1993 (PubMed).
Vojtĕsek, Bártek, Midgley et al.: "An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53." in: Journal of immunological methods, Vol. 151, Issue 1-2, pp. 237-44, 1992 (PubMed).
Gjerset, Arya, Volkman et al.: "Association of induction of a fully tumorigenic phenotype in murine radiation-induced T-lymphoma cells with loss of differentiation antigens, gain of CD44, and alterations in p53 protein levels." in: Molecular carcinogenesis, Vol. 5, Issue 3, pp. 190-8, 1992 (PubMed).
Yeargin, Cheng, Haas: "Role of the p53 tumor suppressor gene in the pathogenesis and in the suppression of acute lymphoblastic T-cell leukemia." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 6 Suppl 3, pp. 85S-91S, 1992 (PubMed).
Cheng, Yee, Yeargin et al.: "Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene." in: Cancer research, Vol. 52, Issue 1, pp. 222-6, 1992 (PubMed).
Stein, Stoica, Tilley et al.: "Rat ovarian granulosa cell culture: a model system for the study of cell-cell communication during multistep transformation." in: Cancer research, Vol. 51, Issue 2, pp. 696-706, 1991 (PubMed).
Vogelstein: "Cancer. A deadly inheritance." in: Nature, Vol. 348, Issue 6303, pp. 681-2, 1991 (PubMed).
Jacquemier, Molès, Penault-Llorca et al.: "p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results." in: British journal of cancer, Vol. 69, Issue 5, pp. 846-52, 1994 (PubMed).
Van Meir, Roemer, Diserens et al.: "Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 4, pp. 1008-12, 1995 (PubMed).
van den Berg, Baas, Polak et al.: "Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid." in: The American journal of pathology, Vol. 142, Issue 2, pp. 381-5, 1993 (PubMed).
Yeargin, Cheng, Yu et al.: "P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines." in: The Journal of clinical investigation, Vol. 91, Issue 5, pp. 2111-7, 1993 (PubMed).